2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-147761
    GAK inhibitor 2 2396706-31-1 98.58%
    GAK inhibitor 2 (Compound 14g) is a potent cyclin G-associated kinase (GAK) inhibitor with an IC50 of 0.024 μM. GAK inhibitor 2 shows antiviral activity with an EC50 of 1.049 μM against dengue virus (DENV).
    GAK inhibitor 2
  • HY-14805S
    Tecovirimat-d4 99.14%
    Tecovirimat-d4 (ST-246-d4) is a deuterium-labelled Tecovirimat (HY-14805). Tecovirimat is an orally bioavailable and selective compound against orthopoxviruses [including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses]. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC50 values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene, which is homologous to vaccinia virus F13L, encoding a major envelope protein (p37) required for production of extracellular virus. Tecovirimat could be used in the study for orthopoxvirus-induced diseases.
    Tecovirimat-d4
  • HY-148187
    NLRP3-IN-11 2769040-91-5 98.79%
    NLRP3-IN-11 is a NLR family pyrin domain containing 3 (NLRP3) proteins inhibitor. NLRP3-IN-11 has biological activity for NLRP3 with an IC50 value of <0.3 μM. NLRP3-IN-11 can be used for the researh of inflammatory and degenerative diseases including NASH, atherosclerosis and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and numerous other autoinflammatory diseases.
    NLRP3-IN-11
  • HY-148348
    AB-836 2445597-31-7 99.13%
    AB-836 is an orally active HBV capsid inhibitor. AB-836 inhibits viral replication by interacting with HBV core protein.
    AB-836
  • HY-148478
    MMV688845 2208962-35-8 99.35%
    MMV688845 is a nontuberculous mycobacteria (NTM) RNA polymerase inhibitor with bactericidal activity against Mycobacterium abscessus and anti-tuberculosis efficacy.
    MMV688845
  • HY-14855A
    (S)-Tedizolid 1431699-67-0 98.21%
    (S)-Tedizolid is the S-enantiomer of Tedizolid. Tedizolid is a novel oxazolidinone with activity against Gram-positive pathogens. (S)-Tedizolid is the less active isomer.
    (S)-Tedizolid
  • HY-148578
    CamA-IN-1 2924055-46-7 99.03%
    CamA-IN-1 is a Clostridioides difficile-specific DNA adenine methyltransferase (CamA) inhibitor. CamA-IN-1 has inhibitory for CamA with IC50 and Kd values of 0.4 μM and 0.2 μM, respectively. CamA-IN-1 can be used for the research of Clostridioides difficile infections (CDI).
    CamA-IN-1
  • HY-149954
    SARS-CoV-2-IN-39 2882823-03-0 99.51%
    SARS-CoV-2-IN-39 (compound 21) is a SARS-CoV-2 inhibitor with an EC50 of 1 μM. SARS-CoV-2-IN-39 against SARS-CoV-2 by inhibiting of SKP2 protein and stabilizing BECN1.
    SARS-CoV-2-IN-39
  • HY-150062
    SARS-CoV-2 nsp3-IN-1 2892105-43-8 ≥98.0%
    SARS-CoV-2 nsp3-IN-1 (Compound 15c) is a Mac1 (SARS-CoV-2 nsp3 macrodomain) inhibitor with the IC50 value of 6.1 μM. SARS-CoV-2 nsp3-IN-1 can inhibit Mac1 ADP-ribosylhydrolase activity. SARS-CoV-2 nsp3-IN-1 demonstrates notable selectivity for coronavirus macrodomains, especially towards SARS-CoV-2 Mac1.
    SARS-CoV-2 nsp3-IN-1
  • HY-150686
    Chitin synthase inhibitor 4 2755847-31-3 99.48%
    Chitin synthase inhibitor 4 (compound 4fh) is a chitin synthase inhibitor with fungicidal effect. Chitin synthase inhibitor 4 is a potential chitin synthase-based fungicide in agriculture.
    Chitin synthase inhibitor 4
  • HY-151402
    Antimicrobial agent-8 2978694-22-1
    Antimicrobial agent-8 (Compound 15) is a potent antimicrobial agent, and shows potent antimicrobial activity with an MIC range of 2-8 μg/mL against Gram-negative and Gram-positive bacteria. Antimicrobial agent-8 shows anti-inflammatory activity against lipopolysaccharide-induced inflammation.
    Antimicrobial agent-8
  • HY-151537
    Gol-NTR 2968461-58-5 99.44%
    Gol-NTR is a Golgi-targetable probe with high selectivity and sensitivity. Gol-NTR is Nitroreductase (NTR)-activated and has visualization acute lung injury (ALI) and repair function. Gol-NTR has a low detection limit of 54.8 ng/mL. Gol-NTR can be used for the research for monitoring and assessing research response of sepsis-induced ALI.
    Gol-NTR
  • HY-152959
    STING agonist-26 2868261-48-5 99.56%
    STING agonist-26 (CF508) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains.
    STING agonist-26
  • HY-153351
    IpOHA 132418-03-2 98.58%
    IpOHA is a potent plant KARI inhibitor. IpOHA also is an antimycobacterial agent with a Ki value of 97.7 nM for Mycobacterium tuberculosis (Mt).
    IpOHA
  • HY-153612
    MMV009085 298217-59-1
    MMV009085 is a potent PfHT1 (Plasmodium falciparum hexose transporter)-specific inhibitor and a potential anti-malarial agent . MMV009085 is also a human glucose transporter inhibitor, it has high potency in inhibiting both glucose uptake (IC50: 2.6 μM in glucose uptake assay) and growth of the parasites (EC50: 1.23±0.04 μM against 3D7).
    MMV009085
  • HY-155007
    DNA gyrase B-IN-2 99.77%
    DNA gyrase B-IN-2 (Compound E) is a 2-aminobenzothiazole-based DNA gyrase B inhibitor with promising activity against ESKAPE bacterial pathogens. DNA gyrase B-IN-2 showed low nanomolar inhibition of DNA gyrase (IC50 < 10 nM) and broad-spectrum antibacterial activity against pathogens belonging to the ESKAPE group, with the minimum inhibitory concentration < 0.03 μg/mL for most Gram-positive strains and 4–16 μg/mL against Gram-negative E. coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.DNA gyrase B-IN-2 can be used for the research of infection.
    DNA gyrase B-IN-2
  • HY-159688
    Cefditoren 104145-95-1 98.14%
    Cefditoren is an orally active antibiotic with broad-spectrum antibacterial activity, capable of inhibiting both Gram-negative and Gram-positive bacteria. It has a MIC50 of 0.25-0.5 mg/L against Streptococcus pneumoniae strains. Cefditoren is effective against respiratory tract infections and skin infections.
    Cefditoren
  • HY-159700
    AA3-DLin 3027565-91-6 ≥99.0%
    AA3-DLin is an ionizable cationic lipid with a pKa value of 5.8. AA3-DLin is used to delivery mRNA combined with lipid nanoparticles (LNPs). AA3-DLin LNP COVID-19 vaccines encapsulating SARS CoV-2 spike mRNAs successfully induces strong immunogenicity in a BALB/c mouse model.
    AA3-DLin
  • HY-161059
    ZB-R-55 2416593-55-8 98.84%
    ZB-R-55 is an orally active RIPK1 inhibitor. ZB-R-55 can be used for sepsis study.
    ZB-R-55
  • HY-161178
    LK-60 99.70%
    LK-60 is a potent DprE1 inhibitor. LK-60 effectively inhibits the proliferation of Mycobacterium tuberculosis. LK-60 has good safety profiles to gut microbiota and human cells.
    LK-60
Cat. No. Product Name / Synonyms Application Reactivity